Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans
ABSTRACT In June 2017, the National Institute of Allergy and Infectious Diseases, part of
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens
AM Sandri, CB Landersdorfer, J Jacob… - Clinical infectious …, 2013 - academic.oup.com
Background. Polymyxin B is a last-line therapy for multidrug-resistant gram-negative
bacteria. There is a dearth of pharmacokinetic data to guide dosing in critically ill patients …
bacteria. There is a dearth of pharmacokinetic data to guide dosing in critically ill patients …
Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of …
M Boisson, M Jacobs, N Grégoire, P Gobin… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Colistin is an old antibiotic that has recently gained a considerable renewal of interest for the
treatment of pulmonary infections due to multidrug-resistant Gram-negative bacteria …
treatment of pulmonary infections due to multidrug-resistant Gram-negative bacteria …
Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models
Background The pharmacokinetic/pharmacodynamic (PK/PD) relationship for polymyxin B
against Klebsiella pneumoniae infections is not known. Methods Dose-fractionation studies …
against Klebsiella pneumoniae infections is not known. Methods Dose-fractionation studies …
Clinical population pharmacokinetics and toxicodynamics of linezolid
LM Boak, CR Rayner, ML Grayson… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Thrombocytopenia is a common side effect of linezolid, an oxazolidinone antibiotic often
used to treat multidrug-resistant Gram-positive bacterial infections. Various risk factors have …
used to treat multidrug-resistant Gram-positive bacterial infections. Various risk factors have …
[HTML][HTML] Functionalisation of brush polyethylene glycol polymers with specific lipids extends their elimination half-life through association with natural lipid trafficking …
M Abdallah, L Lin, IK Styles, A Mörsdorf, JL Grace… - Acta Biomaterialia, 2024 - Elsevier
Polymeric prodrugs have been applied to control the delivery of various types of
therapeutics. Similarly, conjugation of peptide therapeutics to lipids has been used to …
therapeutics. Similarly, conjugation of peptide therapeutics to lipids has been used to …
Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling
Bacterial resistance is among the most serious threats to human health globally, and many
bacterial isolates have emerged that are resistant to all antibiotics in monotherapy …
bacterial isolates have emerged that are resistant to all antibiotics in monotherapy …
Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability …
Pseudomonas aeruginosa remains a challenge in chronic respiratory infections in cystic
fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug …
fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug …
Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance
Infections caused by multidrug-resistant Acinetobacter baumannii are a major public health
problem, and polymyxins are often the last line of therapy for recalcitrant infections by such …
problem, and polymyxins are often the last line of therapy for recalcitrant infections by such …
[HTML][HTML] Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter …
NM Smith, JR Lenhard, KR Boissonneault… - Clinical Microbiology …, 2020 - Elsevier
Objectives Increased rates of carbapenem-resistant strains of Acinetobacter baumannii have
forced clinicians to rely upon last-line agents, such as the polymyxins, or empirical …
forced clinicians to rely upon last-line agents, such as the polymyxins, or empirical …